Dapoflit TM 1000 Tablet contains Dapagliflozin 10mg, Teneligliptin 20mg, and Metformin 1000mg, a powerful triple-drug combination designed for comprehensive management of type 2 diabetes mellitus. This formulation targets multiple pathological mechanisms of diabetes to achieve superior and sustained glycemic control.
Dapagliflozin works by promoting urinary glucose excretion, Teneligliptin enhances insulin secretion and suppresses glucagon release, while Metformin reduces hepatic glucose production and improves insulin sensitivity. Together, they provide effective fasting and postprandial blood glucose control with improved metabolic outcomes.
For hospitals, diabetology clinics, and pharmaceutical distributors, Dapoflit TM 1000 Tablet is a high-demand chronic therapy product, commonly prescribed for patients with uncontrolled diabetes on dual therapy. Its triple-action profile ensures strong acceptance among physicians and consistent repeat prescriptions.
Adding Dapoflit TM 1000 Tablet to your portfolio strengthens your diabetes and metabolic disorder segment, opening opportunities in long-term therapy supply, institutional procurement, retail pharmacy distribution, export markets, and third-party manufacturing. Its clinical relevance and chronic usage make it a commercially strong and high-rotation product.